Cumberland Pharmaceuticals Inc. (CPIX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cumberland Pharmaceuticals Inc. (CPIX) Healthcare & Pipeline Overview

Cumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company focusing on acquiring, developing, and commercializing prescription products for niche markets, including hospital acute care and gastroenterology. With a portfolio of established brands and a pipeline of clinical-stage assets, CPIX operates in the competitive pharmaceutical landscape, balancing growth initiatives with financial discipline.

What Is the Investment Thesis for CPIX?

Cumberland Pharmaceuticals Inc. presents a mixed investment thesis. The company's focus on acquiring and developing niche pharmaceutical products provides opportunities for growth in specialized markets. Cumberland's established portfolio of products, including Acetadote and Caldolor, generates consistent revenue. However, the company's negative profit margin of -17.2% raises concerns about profitability and operational efficiency. The ongoing development of Ifetroban and RediTrex represents potential growth catalysts, but these are subject to clinical trial outcomes and regulatory approvals. With a market capitalization of $112M and a beta of -0.33, CPIX exhibits characteristics of a small-cap stock with lower volatility compared to the broader market. Investors should carefully consider the company's financial performance, pipeline progress, and competitive landscape before making investment decisions.

Based on FMP financials and quantitative analysis

CPIX Key Highlights

Market Cap: $0.05B indicates a small-cap company with potential for growth but also higher risk.

• Profit Margin: -17.2% reflects ongoing challenges in achieving profitability, requiring close monitoring of cost management and revenue growth.
• Gross Margin: 82.9% demonstrates strong pricing power and efficient cost of goods sold management.
• Beta: -0.33 suggests lower volatility compared to the market, potentially offering stability during market downturns.
• Dividend Yield: None (no dividend) indicates that the company is currently reinvesting earnings for growth rather than distributing them to shareholders.

Who Are CPIX's Competitors?

CPIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CPIX's Key Strengths?

Specialized product portfolio targeting niche markets.

• Established relationships with hospitals and physicians.
• Proprietary formulations and intellectual property protection.
• High gross margin of 82.9%.

What Are CPIX's Weaknesses?

Negative profit margin of -17.2%.

• Limited financial resources compared to larger pharmaceutical companies.
• Reliance on a small number of key products.
• Vulnerability to generic competition.

What Could Drive CPIX Stock Higher?

Clinical trial results for Ifetroban in progressive fibrosing interstitial lung diseases.

• Regulatory approval decisions for RediTrex injection.
• Strategic acquisitions of complementary products or companies.
• Geographic expansion into international markets.

What Are the Key Risks for CPIX?

Financial-distress signal — its Altman Z-Score of 0.72 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-29.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory challenges and delays in product approvals.
• Generic competition and pricing pressures.
• Product liability claims and litigation risks.
• Changes in healthcare policies and reimbursement rates.
• Negative profit margin impacting financial stability.

What Are the Growth Opportunities for CPIX?

• Expansion of Ifetroban Clinical Program: Cumberland is developing a clinical program for Ifetroban to treat progressive fibrosing interstitial lung diseases. The market for interstitial lung diseases is substantial, with increasing prevalence and limited treatment options. Successful clinical trials and regulatory approval could lead to significant revenue growth for Cumberland. The timeline for development and commercialization depends on clinical trial progress, but potential market entry could occur within the next 3-5 years.
• Development of RediTrex Injection: RediTrex is being developed for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The market for arthritis and psoriasis treatments is large and growing, driven by an aging population and increasing prevalence of autoimmune diseases. Successful development and commercialization of RediTrex could provide a significant revenue stream for Cumberland. The timeline for development and commercialization depends on clinical trial progress, but potential market entry could occur within the next 3-5 years.
• Strategic Acquisitions: Cumberland Pharmaceuticals can pursue strategic acquisitions of complementary products or companies to expand its portfolio and market reach. The specialty pharmaceutical market is conducive to acquisitions, with numerous opportunities to acquire niche products or companies with established market positions. Successful acquisitions could accelerate Cumberland's growth and diversify its revenue streams. The timeline for acquisitions is opportunistic and depends on market conditions and available targets.
• Geographic Expansion: Cumberland Pharmaceuticals can expand its geographic presence beyond the United States. The international market for specialty pharmaceuticals is substantial, with opportunities to commercialize existing products or develop new products for specific regions. Successful geographic expansion could significantly increase Cumberland's revenue and market share. The timeline for geographic expansion depends on regulatory approvals and market entry strategies.
• Development of Cholesterol-Reducing Agent: Cumberland is developing a product candidate in Phase II clinical trials for a cholesterol-reducing agent for use in the hospital setting. The market for cholesterol-lowering drugs is large, driven by the increasing prevalence of cardiovascular disease. A successful product in this area could provide a significant revenue stream for Cumberland. The timeline for development and commercialization depends on clinical trial progress, but potential market entry could occur within the next 3-5 years.

What Are CPIX's Competitive Advantages?

• Specialized product portfolio targeting niche markets.
• Established relationships with hospitals and physicians.
• Proprietary formulations and intellectual property protection.
• Regulatory exclusivity for certain products.

What Does CPIX Do?

Cumberland Pharmaceuticals Inc., incorporated in 1999 and headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of prescription products. The company targets several therapeutic areas, including hospital acute care, gastroenterology, rheumatology, and oncology, primarily in the United States and internationally. Cumberland's portfolio includes established products such as Acetadote, an injection for acetaminophen poisoning; Caldolor, an injection for pain and fever management; Kristalose, a prescription laxative oral solution; Omeclamox-Pak for Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for hyponatremia; and Vibativ, an injection for serious bacterial infections. Cumberland is also developing RediTrex injection for rheumatoid, juvenile idiopathic, and psoriatic arthritis, as well as psoriasis. The company's pipeline includes Ifetroban, a product candidate in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. Cumberland has also completed Phase II clinical trials for Ifetroban in hepatorenal syndrome and portal hypertension. The company continues to explore the use of Ifetroban to treat progressive fibrosing interstitial lung diseases and is developing a Phase II clinical trial product for cholesterol reduction in the hospital setting. Cumberland's strategy involves acquiring and developing niche pharmaceutical products, focusing on areas with unmet medical needs, and commercializing these products through its sales and marketing infrastructure.

What Products and Services Does CPIX Offer?

• Acquires prescription pharmaceutical products.
• Develops prescription pharmaceutical products.
• Commercializes prescription pharmaceutical products.
• Focuses on hospital acute care products.
• Focuses on gastroenterology products.
• Focuses on rheumatology products.
• Focuses on oncology products.

How Does CPIX Make Money?

• Acquire rights to existing pharmaceutical products.
• Develop new formulations or indications for existing drugs.
• Market and sell products through a specialized sales force.
• Generate revenue through product sales to hospitals, clinics, and pharmacies.

What Industry Does CPIX Operate In?

Cumberland Pharmaceuticals Inc. operates within the specialty pharmaceutical industry, which is characterized by a focus on niche markets and specialized products. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in drug development. Competition is intense, with companies vying for market share through product innovation, strategic acquisitions, and effective marketing. Cumberland's focus on hospital acute care, gastroenterology, rheumatology, and oncology positions it within specific segments of the broader pharmaceutical market. The company's success depends on its ability to develop and commercialize differentiated products that address unmet medical needs.

Who Are CPIX's Key Customers?

• Hospitals and acute care facilities.
• Gastroenterologists and gastroenterology clinics.
• Rheumatologists and rheumatology clinics.
• Oncologists and oncology centers.

Company Profile

Cumberland Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Nashville, US. The company is led by CEO A. J. Kazimi. CPIX has traded publicly since 2009.

Return on equity for Cumberland Pharmaceuticals Inc. stands at -29.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -6.4%, showing how much profit it generates from its asset base. CPIX trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.95 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

CPIX Valuation & Market Position

With a $112M market cap, Cumberland Pharmaceuticals Inc. sits in the micro-cap segment of the market. Relative to its peer group, CPIX's quantitative score of 31/100 is below the peer average of 62/100.

Quarterly Financial Performance: Cumberland Pharmaceuticals Inc.

Revenue for Cumberland Pharmaceuticals Inc. came in at $166K during Q2 2026, a 98.2% contraction versus the preceding quarter. The company recorded a net loss of $4.1M, with diluted EPS of $-0.27. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CPIX averaged $-0.18 in diluted EPS.

Cumberland Pharmaceuticals Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.72 places it in the distress zone, a signal of elevated financial risk.

Cumberland Pharmaceuticals Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 258.3% above estimates on average.

Wall Street analysts project Cumberland Pharmaceuticals Inc. revenue of about $38.2M for fiscal 2026, with EPS near $-0.55.

CPIX Financials

CPIX Latest News

CPIX Analyst Consensus

CPIX MoonshotScore

Common Questions About CPIX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources